Francesco Bertoni
@frbertoni.bsky.social did:plc:am3g2x2ua4npyujnygdinh32
Institute of Oncology Research. President, ICML Local Organizing Committee. USI. Personal opinions only. #lymsm #lymphoma
En Bluesky desde el
- Seguidores
- 130
- Siguiendo
- 190
- Posts
- 65
- Días en rankings
- 0
Resumen
Francesco Bertoni (@frbertoni.bsky.social) es un usuario de Bluesky que se unió el 15 abril 2025. Tiene 130 seguidores, sigue a 190 cuentas y ha publicado 65 posts.
Apariciones en rankings
Los mejores días en que los posts de esta cuenta entraron en la lista diaria de Debya.
Esta cuenta aún no ha aparecido en un ranking diario.
Posts que le gustaron recientemente
Me gusta públicos de la red Bluesky.
Shannon Buckley, Francesco Bertoni, and Justin Taylor discussed "Degraders in Lymphoma" during a plenary session at the AACR Conference on Advances in Malignant Lymphoma. #AACRlymphoma26 @frbertoni.bsky.social
Ver postDegraders in Lymphoma: Shannon Buckley, Francesco Bertoni, and Justin Taylor will address this topic in a plenary session at the AACR Conference on Advances in Malignant Lymphoma (June 24-27; Philadelphia). Learn more: buff.ly/XH3lbfr #AACRlymphoma26 @frbertoni.bsky.social
Ver post#IORnews 🌊 Researchers from the IOR and the University of Galway in Ireland have identified a new natural compound from Irish marine life showing strong potential against an aggressive, hard-to-treat form of blood cancer. Learn more: ior.usi.ch/events-news/...
Ver postYesterday we had our first 19-ICML Local Organising Committee meeting — the behind-the-scenes work for the next edition has officially begun! 💥 @frbertoni.bsky.social #19ICML #ICML #lymphoma #CLL #myeloma #lymssm
Ver post#IORnews A collaborative team from IOR, Dana-Farber Cancer Institute (Harvard Medical School), and biotech iOnctura reports that the novel drug roginolisib may boost the effectiveness of venetoclax in blood cancers such as DLBCL, mantle cell lymphoma, and CLL. Learn more: tinyurl.com/ytybcbr8
Ver post
Cuentas que bloquea
En Bluesky los bloqueos son registros públicos.